New platform gives market access teams the workspace, intelligence and global data to move faster from insight to strategy.
LONDON, UK – 13th July 2026 – Access Infinity today announced the next generation of Nuro™, its market access strategy platform. The new Nuro moves beyond intelligence to become a fully integrated operating environment. It combines the comprehensive HTA, pricing, regulatory and pipeline intelligence it has always been known for with new AI-powered analysis, collaboration, and strategic planning tools, all in one place.
The new platform addresses a persistent challenge for market access teams: powerful intelligence exists, but it remains scattered across disconnected spreadsheets, databases, slide decks, and shared folders. Nuro unifies insight and action in a single platform.
Commenting on this latest evolution of the platform, Thomas Gilboy, Product Owner at Access Infinity, said:
What’s new
Each user now has a dedicated project space within Nuro, structured around their brands, competitors and disease areas. Teams can share workspaces, save analysis, generate new charts and insights, add their own thoughts via notes, and collaborate directly with colleagues, creating a living record of strategic thinking.
A new AI layer enables teams to ask deeper strategic questions grounded in their project context. For example, “What is the best defensive strategy against a payer critique of a new long-acting injectable within our space?” Responses are anchored in Nuro’s data and the team’s own project history, not generic outputs.
Teams can also save, assess, and compare Target Product Profiles (TPPs) against project insights. This is a more advanced and flexible evolution of the existing Virtual Payer Panel, enabling structured side-by-side evaluation of strategic options with evidence drawn directly from the platform.
Related resources:
For more information about Nuro, please visit: accessinfinity.com/nuro
To see Nuro in action, get in touch on accessinfinity.com/nuro-demo-request/
About Access Infinity
Founded in 2014, Access Infinity helps pharmaceutical companies launch and price their products more effectively by combining deep strategic consulting expertise with digital platforms purpose-built for market access and HEOR teams. The company’s experienced consultants work closely with global through to local teams to shape launch strategies, optimise pricing and access, and navigate complex policy landscapes.
Access Infinity’s core digital solutions – Access Hub, Evidence Hub and Nuro – streamline everything from launch tracking and evidence planning to pricing strategy, enabling faster, smarter, and more coordinated decision-making across the product lifecycle. With offices in London, Manchester and Hyderabad, Access Infinity’s clients include many of the pharmaceutical industry’s most influential companies including AstraZeneca, GSK, J&J, MSD, and Pfizer.
For media enquiries, please contact:
Email: louise@accessinfinity.com
Tel: +44 (0)20 4583 5450
